Core Insights - Amgen's stock rose over 4% following positive news regarding its investigational stomach cancer drug, bemarituzumab, which outperformed the S&P 500 index that slid by 0.1% [1][2] Group 1: Drug Development - Bemarituzumab, in combination with chemotherapy, met its primary endpoint of overall survival in a phase 3 clinical trial, showing favorable results compared to patients receiving only a placebo [2][4] - The study involved 547 patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancer, highlighting the significance of the drug in addressing a major health issue, as gastric cancer is the fifth-leading cause of cancer-related death globally, with over 650,000 fatalities [4] Group 2: Analyst Reactions - Analysts reacted positively to the trial results, with Piper Sandler's David Amsellem maintaining an overweight (buy) recommendation and setting a price target of $328 per share, indicating confidence in the drug's potential despite some concerns [5] - The overall sentiment among analysts suggests that Amgen may be on the verge of a successful drug launch, with optimism surrounding the advancements in cancer treatment [6]

NASDAQ:ZLAB | HKEX:9688 © 2025. Zai Lab. All Rights Reserved. Forward-Looking Statements This presentation contains forward-looking statements, including statements relating to our strategy and plans; potential of and expectations for our business, commercial products, and pipeline programs; our goals, objectives, and priorities and our expectations under our growth strategy (including our expectations regarding our commercial products and launches, clinical stage products, revenue growth / CAGR, profitabil ...